Market capitalization | $75.70m |
Enterprise Value | $54.55m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.46 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-29.40m |
Free Cash Flow (TTM) Free Cash Flow | $-17.94m |
Cash position | $21.26m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
4 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
4 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.27 -0.27 |
50%
50%
|
|
EBITDA | -29 -29 |
33%
33%
|
EBIT (Operating Income) EBIT | -29 -29 |
33%
33%
|
Net Profit | -27 -27 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Head office | Canada |
CEO | David Elsley |
Employees | 22 |
Founded | 2017 |
Website | www.cardiolrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.